INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue?

Inspire Medical Systems INSP stock has gained 39.7% in the past three months, underperforming the Medical Information Systems industry's 48.2% gain while outperforming the S&P 500's 2.2% rise during the period. The rally reflects improving investor confidence as reimbursement headwinds begin to ease and management doubles down on long-term growth initiatives.

Inspire Medical reinforced this optimism with a stronger-than-expected second quarter. Although revenues declined 7.6% year over year to $200.6 million due to temporary coding disruptions, adjusted earnings per share (EPS) beat expectations, operating cash flow improved sharply, and the company raised its 2026 revenue, operating margin and adjusted EPS outlook. The launch of Project Horizon and growing adoption of Inspire V further strengthen its long-term growth outlook.

What Is Fueling INSP’s Growth?

Project Horizon Is Creating a Stronger Growth Engine: Inspire Medical launched Project Horizon to accelerate long-term revenue growth by improving patient flow and expanding access to therapy. The initiative is expected to create roughly $30 million in annualized investment capacity through organizational optimization and supply-chain efficiencies. Management plans to reinvest these savings into patient education, engagement and prior-authorization support, which should help drive growth beyond 2026.

Inspire V Adoption Continues to Strengthen: Inspire V remains a major growth catalyst for the company. The new system helped expand gross margin through a richer product mix, while management said it accounted for the majority of implants during the second quarter. The company also highlighted strong clinical data demonstrating the system's safety, efficacy and potential cardiovascular benefits, reinforcing its competitive positioning.

Reimbursement Clarity Is Supporting Recovery: The reimbursement environment is gradually becoming more favorable. Inspire Medical said C-codes are now in place, reimbursement rates remain intact and prior-authorization trends are improving as providers become more comfortable with updated billing processes. The company expects reimbursement-related headwinds to ease sequentially through the second half of 2026, providing a clearer path toward revenue recovery. 

A Large Untapped Market Supports Long-Term Expansion: Inspire Medical continues to target a significant untreated obstructive sleep apnea population. Management believes growing clinical evidence, expanding physician education and broader international adoption can support future growth. The company is also working to expand surgeon capacity and simplify patient screening through the PREDICTOR study, which could reduce diagnostic hurdles and improve access to therapy.

Image Source: Zacks Investment Research

INSP’s Estimates

The Zacks Consensus Estimate for INSP’s 2026 and 2027 EPS implies a year-over-year decline of 48.8% and growth of 22.7%, respectively, to $1.24 and $1.52. In the past 60 days, the consensus mark for the company's 2026 EPS has improved by 31 cents.

Revenues for 2026 are projected to decline 6.7% to $851.2 million and improve 4.4% to $888.4 million in 2027.

Risks and Challenges

Inspire Medical’s recovery still depends heavily on execution. Coding and reimbursement disruptions continue to weigh on U.S. procedure volumes, and management expects these issues to remain a headwind through the second half of 2026. While prior-authorization trends are improving, the pace of recovery remains uncertain.

The company is also investing aggressively through Project Horizon, and the benefits may take time to materialize. In addition, future reimbursement decisions, including the proposed CPT code process and Medicare payment updates, remain important variables for the long-term growth outlook.

Inspire Medical Systems, Inc. Price

Inspire Medical Systems, Inc. price | Inspire Medical Systems, Inc. Quote

Conclusion

INSP’s recent rally reflects growing confidence that its temporary reimbursement challenges are becoming more manageable. Stronger-than-expected profitability, improving cash generation, growing Inspire V adoption and Project Horizon's growth investments provide a solid foundation for future expansion. The company's raised 2026 outlook and improving reimbursement trends further strengthen the long-term investment case.

While coding-related disruptions and reimbursement decisions remain important watch points, Inspire Medical’s expanding clinical evidence, operational discipline and large untapped sleep apnea market position it well for sustained long-term growth. Backed by a Zacks Rank #1 (Strong Buy), the stock appears well-positioned for investors seeking exposure to an innovative medical technology leader.

Other Stocks to Consider

Some other top-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO.

Globus Medical, currently sporting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research